Midterm follow-up of patients who underwent removal of a left ventricular assist device after cardiac recovery from end-stage dilated cardiomyopathy  by Hetzer, Roland et al.
In contrast to the past, when analysis of cardiac tissue
was done when cardiac function had severely deterio-
rated, the use of cardiac assist devices has enabled us
for the first time to examine myocardial tissue at the
time of considerably deteriorated cardiac function and
In a subset of patients with end-stage idiopathic dilatedcardiomyopathy (IDC) who required a mechanical
cardiac assist device, we recently found that removal
could be conducted without transplantation after the
recovery of cardiac function.1,2
Objective: Cardiac recovery in end-stage idiopathic dilated cardiomyopathy
recently occurred after temporary support with a left ventricular assist
device. We report the case histories of patients who underwent removal of
the device more than 4 years ago.
Methods: Since June 1994, 23 patients with end-stage idiopathic dilated car-
diomyopathy who were supported by a left ventricular assist device or biven-
tricular assist device for 1 to 26 months (mean, 6 months) underwent
removal of the device after complete or extensive cardiac recovery, as
revealed by echocardiography.
Results: Seven patients (group A) had recurrent cardiac failure after 4 to 24
months. Transplantation was performed in 6 patients, and one died while on
the waiting list. Three patients died of noncardiac causes within a period of
4 months and 3 days after removal of the assist device. Stable cardiac recov-
ery occurred in 13 patients (group B) for 3 to 49 months (mean, 23 months).
At the time of implantation, there were no significant differences between
the groups with regard to age, hemodynamics, left ventricular ejection frac-
tion, left ventricular internal diameter in diastole, and autoantibody levels.
The increase of ejection fraction and the decrease of left ventricular internal
diameter in diastole after 2 months were highly significant. The patients in
group A had longer histories of heart failure and first cardiac symptoms and
duration of assist when compared with group B. Group B demonstrated a
quicker cardiac recovery on the assist device, and thus support was shorter.
Also, the degree of recovery at assist device explantation was more complete
in group B. The age at the time of device placement was the only influenc-
ing factor for duration on the assist device. The probability of recurrence of
heart failure was influenced by the duration of heart failure.
Conclusions: In selected patients with idiopathic dilated cardiomyopathy,
lasting recovery can be achieved after unloading with a left ventricular assist
device. Lasting cardiac recovery seems to be related to functional normal-
ization and a more rapid recovery during the unloading period. (J Thorac
Cardiovasc Surg 2000;120:843-55)
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subsequently when cardiac function has been improved
as a result of mechanical decompression of the heart.
Therefore, discussion has focused on several questions,
which have opened up a host of new and ongoing
research activities. The interesting questions that arise
today are as follows:
1. Which type of assist system and ventricular unloading
modus would allow recovery?
2. What degree of recovery reached during the assist peri-
od is consistent with the prospect of durably restored
cardiac function?
3. What kind of medication would support the mainte-
nance of the once-reached cardiac recovery state?
4. What type of myocardial disease is amenable to cardiac
recovery? In particular, could this be an IDC or rather
chronic myocarditis?3-5
5. What are the molecular changes of the myocardium
after the heart has recovered with the aid of mechanical
unloading?5
Although questions 4 and 5 await a future that is
dependent on larger patient numbers and increased
intensity of research in this field, at least the initial
doubts as to whether cardiac recovery might last for a
longer period can be answered positively on the basis
of our present experience with 23 such patients whose
clinical status after device removal is outlined in this
report.
Patients and methods
Between June 1994 and January 1999, 84 patients with
end-stage heart failure were supported with either a Novacor
(n = 63; Baxter Healthcare Corp, Novacor Division, Oakland,
Calif) or a TCI (n = 21; Thermo Cardiosystems, Inc, Woburn,
Mass) left ventricular assist device (LVAD).
Of this cohort, 65 patients had IDC, and 19 had ischemic
cardiomyopathy. Patients with ischemic heart disease were
excluded from the study. Of the group with IDC, 23 under-
went removal of the LVAD when cardiac function had under-
gone complete or near-complete restoration during a decom-
pression period of between 30 and 794 days.
The 42 patients with IDC who did not attain cardiac func-
tional improvement to near normal values were also exclud-
ed from the study. At the time of device placement, these 42
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Table I.  Patient demographic data and follow-up observations
Year Duration 
Patient of on assist Type of Group
No. implantation support (d) assist device Follow-up observation (A, B, or C)
1 1994 160 Novacor LVAD Persistent recovery since 4 y, working B
2 1994 243 Novacor LVAD Persistent recovery since 45 mo, working B
3 1994 347 Novacor LVAD Persistent recovery, died after 2.5 y because of chronic infection of B
left ventricular apex
4 1995 200 TCI LVAD Persistent recovery since 41 mo, working B
5 1996 200 Novacor LVAD Recurrent heart failure, died after 2 y during left heart catheter A
6 1994 794 Novacor LVAD Recurrent heat failure, LVAD (Berlin Heart) after 7 mo, heart A
transplantation
7 1996 66 Novacor LVAD Died after 4 mo, pulmonary embolism C
8 1996 201 Novacor LVAD Recurrent heart failure, heart transplantation A
9 1996 30 Novacor LVAD Persistent recovery since 26 mo B
10 1996 67 Novacor LVAD Persistent recovery since 26 mo, working B
11 1996 233 Berlin Heart BVAD Recurrent heart failure, heart transplantation after 17 mo A
12 1996 418 Novacor LVAD Recurrent heart failure, heart transplantation after 6 mo A
13 1996 105 Novacor LVAD Died after 8 d, pulmonary bleeding C
14 1996 181 TCI LVAD Recurrent heart failure, heart transplantation after 4 mo A
15 1997 62 Novacor LVAD Persistent recovery since 21 mo, working B
16 1997 51 Novacor LVAD Persistent recovery since 21 mo B
17 1997 83 Novacor LVAD Recurrent heart failure, heart transplantation after 7 mo A
18 1997 74 Novacor LVAD Persistent recovery since 19 mo, working B
19 1997 36 Novacor LVAD Persistent recovery since 18 mo, working B
20 1997 54 Novacor LVAD Died after 3 d, septic shock C
21 1997 48 Novacor LVAD Persistent recovery since 14 mo, working B
22 1998 62 Novacor LVAD Persistent recovery since 12 mo, working B
23 1998 224 TCI LVAD 3 mo without LVAD, stable B
Mean 171
Range 30-794
SD 174.6
Group A, Recurrence of heart failure (n = 7); group B, lasting cardiac recovery (n = 13); group C, death after weaning (n = 3).
patients showed a mean left ventricular ejection fraction
(LVEF) and a left ventricular internal diameter in diastole
(LVIDd) of 17% ± 5% and 77 ± 10 mm, respectively.
During follow-up, they improved to mean optimal left ven-
tricular values of LVEF (35% ± 8%) and LVIDd (59 ± 6 mm),
which seemed to us to be insufficient for removal of the assist
device.
There were 22 men and 1 woman with ages at the time of
LVAD implantation that ranged from 18 to 64 years. All had
some, mostly insignificant, symptoms of cardiac disease that
dated back to between 1 and 30 years previously. The history
of manifest heart failure was quite variable and ranged from
6 months to 17 years (Table I).
At the time of LVAD implantation, the patients had invari-
ably reached a state of conventionally untreatable heart fail-
ure, and they were receiving intravenous inotropic medica-
tion, predominantly dopamine and dobutamine, which in
some instances was combined with phosphodiesterase
inhibitors, or epinephrine. No lasting improvement was
observed despite such medication. Hemodynamic data
revealed elevated pulmonary artery pressures and a depressed
cardiac index LVIDd that ranged from 62 to 92 mm and
severely impaired ventricular function with LVEF data of
between 10% and 20% (Table II). Implantation of an LVAD
was decided on as an emergency procedure in all patients,
with the primary goal of keeping the patient alive until a later
cardiac transplantation could be performed.
Nineteen patients received a Novacor 100 system (Baxter),
one patient received an air-driven TCI HeartMate 1000 IP
system (Thermo Cardiosystems, Inc), two patients received
an electrically driven TCI HeartMate 1000 vented electric
system, and one, who needed biventricular support, received
the pneumatically driven Berlin Heart system (Mediport
Kardiotechnik, Berlin, Germany) with a trans–left
atrial–transmitral cannula, which directly drained the left
ventricle.
After assist device implantation, repeated trans-
esophageal echocardiography was performed by the same
operator, and the cardiac dimensions and the ventricular
functions were measured. When improvement of LVIDd
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Table II.  Patient hemodynamic characteristics and autoantibodies at the time of assist device placement
Preimplantation status
Age First Manifest
at cardiac heart Mean
Patient implant symptoms failure Inotropic CI PAP Autoantibodies
No. Sex (y) (y) (y) drugs (L · min–1 · m–2) (mm Hg) (LU)
1 M 38 4 1 Dopamine, dobutamine 1.5 36 5.9
2 M 42 2 2 Dopamine, dobutamine 1.4 38 7
3 M 58 4 1 Dopamine, dobutamine 1.4 40 7
4 M 52 4 4 Epinephrine, dopamine, 1.5 33 5.2
dobutamine, phosphodiesterase inhibitor
5 M 55 7 4 Dopamine, dobutamine 1.5 34 8.2
6 M 37 5 <1 Dopamine, dobutamine 1.9 28 5.4
7 M 36 4 4 Dopamine, dobutamine, epinephrine 1.8 41 6.1
8 M 47 >13 13 Epinephrine 1.7 37 5.5
9 M 32 3 3 Dopamine, dobutamine 1.8 31 4
10 M 42 1 1 Dopamine, dobutamine 2.0 33 4.2
11 M 53 12 7 Dopamine, epinephrine 1.9 35 7.1
12 M 61 30 8 Dopamine, epinephrine 1.8 31 3.4
13 F 58 9 2 Dopamine, dobutamine 1.7 34 5.4
14 M 64 5 3 Dopamine, dobutamine 1.4 45 2.9
15 M 43 6 4 Dopamine, dobutamine 1.6 18 4.4
16 M 41 4 1 Dopamine, dobutamine 1.5 24 5.5
17 M 35 24 17 Epinephrine, dopamine, 1.4 47 8.3
phosphodiesterase inhibitor
18 M 42 1 1 Epinephrine 1.1 31 6.4
19 M 22 1 1 Dopamine, dobutamine, 2.2 43 4.6
phosphodiesterase inhibitor
20 M 18 1 1 Dopamine 1.8 38 6.5
21 M 31 <1 <1 Dopamine, dobutamine 2.2 31 4.6
22 M 41 >1 1 Dopamine, dobutamine 1.9 37 5.3
23 M 56 10 2 Dopamine, dobutamine 1.7 32 5.2
Mean 43.7 6.6 3.7 1.7 34.7 5.6
Range 18-64 <1-30 <1-17 1.1-2.2 18-47 2.9-8.3
SD 12.1 7.4 4.2 0.27 6.52 1.4
CI, Cardiac index; PAP, pulmonary artery pressure.
and LVEF was noted, the investigations were repeated dur-
ing short periods of pump halt of up to 20 minutes, with
one single pump stroke every 20 seconds. Once the deci-
sion for LVAD explantation had been made, all the patients
with the Novacor and TCI devices had their pumps repro-
grammed to a fixed-rate pumping mode on the assumption
that this would exert some load on the left ventricles and
train them before explantation.
The prospect of elective pump explantation was taken into
consideration when, on repeated investigation, the LVIDd had
dropped below 60 mm and the LVEF had risen to more than
40%. This was the case in patients 1 to 5, 8 to 10, 12, 13, 15
to 17, and 20 to 23. Elective explantation was performed in
all after between 1 and 14 months (mean, 5 ± 4 months) of
assist duration.
In patients 6, 7, 11, 14, 18, and 19, complications derived
from the assist systems prompted us to remove the assist
device, although the degree of recovery was not considered
optimum in every instance (patients 6, 11, and 14). Thus,
explantations were performed after 36 to 181 days (mean, 89
± 34 days) of assist support.
The procedure of assist device removal was based on the
principle of leaving the heart as unmolested as possible.
Thus, for the patients with Novacor and TCI devices, the
pump housing pocket in the left upper abdominal wall
quadrant was entered, the inflow and outflow cannulas
were transected in their Dacron graft portion, the pump was
removed, and the remainder of the cannulas leading to the
left ventricular apex and to the ascending aorta were left in
place and securely oversewn. In the patients with a TCI
device, an additional left-sided thoracotomy was per-
formed to reach the Dacron part of the otherwise titanium-
covered inflow cannulas. In the patient with a biventricular
assist device (BVAD) and a transmitral cannula, rester-
notomy was performed, and the cannulas were removed
without extracorporeal circulation.
After assist device explantation, the patients began taking
anticoagulants (Coumadin) for 6 months because the cannulas
had been left in situ, and it was assumed that the apex cannula
might become an origin of thromboembolism. In addition, β-
blocker angiotensin-converting enzyme (ACE) inhibitors and
aldosterone antagonists were administered permanently.
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Table III.  Patient echocardiographic data
Echocardiography
LVEF (%)
Patient Before assist After Before After Latest died or Present 
No. device 2 mo explantation explantation listed for transplant permanent recovery
1 15 65 55 50 49
2 15 40 45 45 51
3 10 35 48 45 45
4 12 35 45 48 50
5 15 33 41 43 33
6 15 30 35 38 28
7 14 50 47 47 40
8 16 40 40 36 31
9 15 * 50 50 33
10 17 49 44 50 37
11 18 35 38 37 20
12 20 24 40 35 32
13 18 30 40 45 45
14 20 40 40 35 17
15 15 49 49 49 45
16 15 49 49 50 43
17 15 47 47 41 25
18 15 44 44 45 35
19 20 * 45 50 50
20 15 60 60 53 53
21 15 50 50 50 49
22 19 48 48 58 49
23 10 39 50 50 50
Mean 15.6 42.5 45.7 45.7 33.5 45.1
Range 10-20 24-65 35-60 35-58 17-53 33-51
SD 27 10.1 5.7 6.2 11.2 6.5
*The assist system of patients 9 and 19 were explanted after 30 and 36 days, respectively.
Before, during, and after the assist period, a spectrum of
studies were conducted into the morphology of the myocardi-
um, the immunohistology, and the autoantibodies against car-
diac structures and the mediators of IDC. Because none of the
data of these studies have reached a state where they could
provide convincing predictors of the potential for myocardial
recovery, they will be presented at a later time on the basis of
larger data numbers.
Three groups were formed because of the clinical need of
further interventions as a result of recurrence of heart failure
(group A), stable clinical status (group B), and death of the
patients (group C, Table I).
Statistical analysis. Our statistical model contained 2
dependent variables (LVEF and LVIDd) and 3 independent
variables (group allocation, age at the time of device place-
ment, and repeated measures).
Analysis of variance (ANOVA) was performed to calculate
the significance of the independent variables. We used the
Duncan multiple-range test as a mean separation test. Because
the requirements for ANOVA were not completely satisfied in
all variables, the results of the ANOVA were confirmed by
means of a nonparametric test (Kruskal-Wallis). The results of
repeated measures were confirmed by use of the Wilcoxon test.
A Cox model was developed to test for variables that influ-
ence the time with an assist device and the recurrence of heart
failure.
Results
Of the 23 patients, 13 have since had stable cardiac
function without any signs of deterioration of echocar-
diographic data both in left ventricular dimensions and
in LVEF in the majority. In 3 patients of this group
(patients 9, 10, and 18), some decline of cardiac func-
tion parameters has been observed, although without
clinical relevance to date (Table III).
Cardiac stability has now been observed for between
3 months and 4 years (mean, 23 ± 14 months) as of
April 1999. This has been seen in 3 patients for more
than 3 years, in 11 for longer than 1 year, and in 1 for
a shorter time. In some instances (patients 2 and 4) fur-
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Echocardiography
LVIDd (mm)
Before After Before After Latest died  or Present 
assist device 2 mo explantation explantation listed for transplant permanent recovery
72 42 48 58 58
70 50 46 48 51
70 64 54 56 61
69 47 49 52 54
78 42 43 56 58
74 60 64 55 68
77 52 42 43 55
72 59 64 67 68
73 * 40 41 66
77 60 55 60 72
84 65 52 62 80
84 54 66 68 72
68 57 51 50 50
77 53 66 67 75
83 55 59 60 65
64 55 55 54 59
82 56 56 59 77
93 54 54 58 67
81 * 48 51 56
62 40 40 54 54
78 50 50 53 55
67 55 55 54 56
81 59 50 50 56
75.5 53.8 52.5 55.5 65.3 59.6
62-93 40-65 40-66 41-68 50-80 51-72
7.4 6.8 7.8 6.9 10.2 6.4
ther improvement of cardiac function was noted, even
after removal of the assist device (Table III).
Seven patients had recurrent heart failure 4 to 24
months (mean, 11 ± 7 months) after pump explantation.
In 1 patient (patient 6) another assist system (Berlin
Heart LVAD from the left ventricular apex to the
descending aorta) had to be implanted by means of a
left thoracotomy in an emergency situation. This
patient and patients 8, 11, 12, 14, and 17 underwent
heart transplantation between 4 and 17 months after
removal of the assist device.
Four patients died of causes unrelated to heart failure,
1 patient (patient 20) on day 3 after pump removal
because of septic shock, 1 (patient 13) on day 8 from
massive pulmonary bleeding, 1 (patient 7) after 4
months as a result of a pulmonary embolism, and 1
(patient 3) after 2.5 years because of a severe infection
of the myocardium at the site of the apical cannula. The
3 patients who died within 4 months of device removal
were excluded from the comparison and statistical
analysis.
In patients 2 to 4, in whom chronic infections of the
pump pocket had been observed, chronic suppuration
and fistulas recurred, which required secondary
removal of the ascending graft in patients 2 and 4 after
21 and 20 months, respectively, and removal of the api-
cal cannula in patients 3 and 4 after 21 and 20 months,
respectively. Whereas in patients 2 and 4 the further
course has since been uneventful for 45 and 41 months,
respectively, chronic apex infection in patient 3 led to
recurrent sanguination that necessitated two successive
emergency operations. The patient died of the sequelae
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Fig 1. Mean LVEF and LVIDd at the time of implantation (pre-assist), 2 months after device placement (after 2
months), before explantation (pre-explant), and 1 week after device removal (post-explant).
Fig 2. Differences in mean LVEF and LVIDd before and after device placement with regard to the 4 age groups.
after a catastrophic hemorrhage, even though he still
had well-preserved cardiac function up to the very end.
An ANOVA for the time before and after device
placement (repeated measures) with LVEF and LVIDd
as dependent variables showed statistical significance
for both parameters (P = .0001). After 2 months, there
was a significant increase of LVEF and a significant
decrease of LVIDd (Fig 1).
For LVEF, the factor age classes (18-35, 36-45, 46-
55, and 56-64 years of age) showed no significance
before implantation. Two months after implantation,
factor age classes showed an overall significance (P =
.0002, Fig 2). Those patients who were younger than
46 years of age had significantly higher values for
LVEF than the older patients. For LVIDd, factor age
classes showed no significance.
Furthermore, preimplantation LVEF and LVIDd
showed no significance for factor group (A, B, and C).
For LVEF 2 months after implantation, the factor group
(A, B, and C) had highly significant results (P = .003),
although not for LVIDd. After 2 months, group A
showed significantly lower values for LVEF (Fig 3).
An analysis of the data before and after device explan-
tation (repeated measures) showed statistical significance
for LVIDd (P = .01) but not for LVEF. After explantation,
there was a significant increase of LVIDd (Fig 1).
A significant difference was also found between the
age classes. The patients who were younger than 36 years
had significantly higher values for LVEF when compared
with the older ones (before explantation, P = .002; after
removal, P = .0001; Fig 4). The factor group showed sig-
nificance before explantation (P = .0002) and after
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Fig 3. Differences in mean LVEF and LVIDd before and after device placement with regard to group A (recurrence
of heart failure), group B (lasting recovery), and group C (death after weaning unrelated to cardiac function).
Fig 4. Differences in mean LVEF and LVIDd before device removal and 1 week thereafter with regard to the 4 age
groups.
explantation (P = .0001, Fig 5). Before and after explan-
tation, group A showed significantly lower LVEF values.
The significance pattern for LVIDd is different. A dif-
ference between the groups could be observed before
(P = .003) and after explantation (P = .0006). The
patients in group A had significantly higher values for
LVIDd before and after device removal when compared
with both other groups.
Additionally, the following significant differences
were visible with regard to the groups. Significant dif-
ferences could be detected for the variable duration on
assist support (P = .04), first cardiac symptoms (P =
.004), and manifest heart failure (P = .004).
The duration on assist support in group A was signif-
icantly longer than that in group C. The time of first
cardiac symptoms and manifest heart failure in group A
was significantly greater than in groups B and C.
A stepwise regression model, according to Cox,
revealed that the probability of nonexplantation
decreased with time on assist support (Fig 6).
Furthermore, the age at the time of device implantation
was the only influencing factor for the duration on
assist device (P = .02, Fig 6).
The functional relationship between the age at the
time of device placement and duration on assist support
could be best fitted by a hyperbolic function with an r2
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Fig 5. Differences in mean LVEF and LVIDd before device removal and 1 week thereafter with regard to group A
(recurrence of heart failure), group B (lasting recovery), and group C (death after weaning unrelated to cardiac
function).
Fig 6. Results of a Cox regression model (survival analysis). The cumulative probability of nonexplantation over
the time on assist support.
value of 0.48. A further Cox model revealed that the
probability of recurrence of heart failure decreases with
increasing follow-up time (Fig 7). The variable dura-
tion of heart failure does significantly influence the
probability of recurrence of heart failure and therefore
the need for cardiac transplantation (P = .02).
Discussion
The data of the patients presented in this report
demonstrate that lasting recovery of cardiac function for
at least several years can be achieved by prolonged
LVAD support for end-stage heart failure caused by IDC
in some patients. The potential of erstwhile severely
dilated and impaired hearts toward such a functional
restoration has been observed by several investigators;
however, it has remained doubtful whether such a recov-
ery might be transient and whether a relapse of heart fail-
ure might occur as a rule.6-11 In fact, 7 of our 23 patients
who underwent assist device explantation when we
believed their hearts were sufficiently recovered did have
a recurrence of heart failure and had to undergo cardiac
transplantation.
Statistical analysis of the available data shows a sig-
nificant improvement of LVEF and LVIDd before and
after 2 months of assist device placement. However, for
the time before and after device removal, LVIDd
revealed significant re-enlargement, whereas LVEF
remained unchanged. Enlargement of the left ventricle
expresses higher volume load caused by the missing
pump and has to be accepted as a normal adaptation
process after device removal. The constant LVEF
demonstrates, however, that because of the reverse
remodeling of the myocardium by application of the
assist device, there is an increased and obviously stable
contractility.
An analysis of whether the age of the patients may
have an influence on changes in LVEF and LVIDd
revealed that age had no influence before device place-
ment but that it had a significant overall influence on
both parameters 2 months after implantation. The heart
function of younger patients improved significantly
more than that in older patients. Even so, with regard to
LVEF before and after device removal, younger patients
showed considerably better function. Obviously,
younger patients have a higher potential for recovery. Of
course, there are those with a shorter time of first cardiac
symptoms and manifest heart failure. Unfortunately,
there were no data available to examine why younger
patients have a higher potential for recovery (eg, whether
they might have less replacement fibrosis or differences
in the extracellular matrix). An analysis of the differ-
ences between groups A, B, and C revealed significant
overall differences. Although no group differences were
seen before device placement or 2 months after device
implantation, significant differences were observed 2
months later with regard to LVEF and LVIDd. In group
A, LVEF had improved less after 2 months. Even so,
before and after explantation, LVEF and LVIDd were
significantly lower or higher, respectively, when com-
pared with that found in groups B and C. Although
LVEF might not be an ideal parameter to assess cardiac
function because of its dependence on different hemo-
The Journal of Thoracic and
Cardiovascular Surgery
Volume 120, Number 5
Hetzer et al 851
Fig 7. Results of a Cox regression model (survival analysis), showing the cumulative probability of heart failure
nonrecurrence.
dynamic conditions, it is easy to measure and seems to
have considerable value for clinicians to predict the out-
come after weaning from the assist device. Together with
the Cox model that was calculated, it can be estimated
that patients with a shorter duration of heart failure with
a consequently higher LVEF had a lower probability for
the development of recurrence of heart failure with the
need for transplantation.
Lasting recovery seems to be related to patients with
a shorter history of heart failure and also to a more
rapid restoration of normal heart function initially after
assist device implantation. This would support the
assumption that recovery is more likely in a type of car-
diac disease with an ongoing inflammatory component,
which may be termed chronic myocarditis. Our experi-
ence with acute myocarditis in children who displayed
fast recovery from complete heart failure and cardiac
arrest during BVAD support of 1 and 2 weeks’ duration
would underline the importance of inflammation.12,13
A significant difference could be discerned in the
completeness of the cardiac recovery at the time of
assist device explantation. The patients with lasting
recovery (group B) had attained entirely normal func-
tion values, whereas the patients who had a relapse
(group A) had a somewhat less than complete recovery.
In an earlier study, we also found that during the
assist period, some patients reached a maximum of
recovery with a subsequent decline followed by a later
relapse. These patients had more frequently been in
group A with such a missed optimum status.
Interpretation was that ventricular unloading had
occurred for too long, which may finally have resulted
in cardiac atrophy.14
The type of LVAD seems to be important because
complete drainage of the left ventricle appears to be
mandatory to enable the heart to recover. This has been
the case with the Novacor and the TCI systems, which
both have large-bore inlet cannulas at the apex of the
left ventricle and provide the most complete ventricular
drainage. Atrial drainage appears to be unsuitable. At
our institution, in more than 300 applications of the
pneumatically driven Berlin Heart system and atrial
drainage,15 cardiac recovery was observed not once. In
the 1 patient with a BVAD in the patient group pre-
sented here, a transmitral atrial cannula was used,
which allowed ventricular drainage, and cardiac recov-
ery was observed. This patient, however, had recurrent
heart failure and underwent transplantation. At explan-
tation of the heart, fibrosis of the anterior mitral leaflets
was observed, a fact which casts severe doubts on the
longer use of such a cannulation system. However,
short-term applications of such a system may be suc-
cessful without cardiac structure damage, as docu-
mented in children with acute myocarditis.13
On explantation of the Novacor and the TCI sys-
tems, the outflow and inflow cannulas were left in
place. Explantation was commenced in patients with
the Novacor device by opening the pocket that con-
tains the device and ligating both the inflow and out-
flow conduits from below the diaphragm and in
patients with TCI devices through an additional left
thoracotomy to the inflow cannula. There has been
concern about the complications that arise from these
remnants. However, we have never observed any
thromboembolism, whereas there have been 3
instances of graft infection that required removal of
the infected cannulas. This was successful in 2
patients and proved incurable and eventually lethal in
the third case. These graft infections were all
observed in the first 4 patients weaned. Since that
time, we have removed the cannulas and the sur-
rounding cage as extensively as possible, and we
have not seen any infection in the patients subse-
quently.
Permanent medical treatment with ACE inhibitors
and β-blockers has been considered important to
ensure lasting cardiac recovery after assist device
explantation. This follows the experience that inhibi-
tion of the neurohumoral activation by ACE inhibitors
and β-blockade has a positive effect on cardiac func-
tion and additionally is essential to influence the under-
lying disease process in IDC, where autoimmune
aggression against β-receptors seems to play some role,
as documented by our experience with immunoadsorp-
tion of such antibodies.16,17
Thus, a somewhat clearer view has been achieved
as to the prospect of myocardial recovery in IDC
once the patient has been placed on an LVAD.
However, no reliable predictors have been found with
regard to the most important question of which
patients with IDC might be candidates for an unload-
ing and weaning protocol before assist device
implantation. The only factor detected that influences
the probability of heart failure is the duration of heart
failure. Nevertheless, according to our overall experi-
ence with the weaning procedure, approximately
20% of the patients with an LVAD system who sur-
vive on the device can be weaned and expect durable,
midterm, stable cardiac function.
We are grateful for the editorial assistance from Tonie
Derwent. We are indebted to Mrs Anette Gaußmann, who
provided the illustrations.
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Discussion
Eric A. Rose (New York, NY). I congratulate Dr Hetzer and
his colleagues for their pioneering efforts in describing what
is now called by many the bridge to recovery scenario.
This series is the largest single-center patient experience I
am aware of in which spontaneous recovery of myocardial
function was observed in candidates for transplantation in
whom LVADs are initially intended as a bridge to transplan-
tation. Our own smaller experience at Columbia with 7
patients parallels that described by the Berlin group.
This intriguing observation now gives rise to more ques-
tions than answers. First and foremost are questions related to
identification of the small subset of patients bridged to trans-
plantation whose myocardium improves in this setting. Dr
Hetzer’s data suggest that patients with shorter durations of
heart failure before implantation and those with early evi-
dence of myocardial recovery after device implantation have
the most favorable outcomes. This series includes only
patients with IDC, yet we and others have also observed
recovery in a small number of patients with ischemic left ven-
tricular dysfunction.
My first question for Dr Hetzer focuses on the denomina-
tor of total patients bridged to transplantation. In our experi-
ence only approximately 5% of these patients spontaneously
improved enough to allow explantation. What percentage of
all patients receiving devices in Berlin have had explantation?
Second, I invite Dr Hetzer to speculate on whether he
believes that active strategies to enhance spontaneous recov-
ery (eg, cellular transplantation or gene therapies designed to
improve myocardial function) might increase the frequency
of recovery in the future.
Numerous technical details may also play a role in this
phenomenon. Dr Hetzer suggests that complete left ventricu-
lar unloading is important. Have the Berlin investigators
looked at any partial unloading regimens designed perhaps to
wean patients from these devices?
Dr Hetzer also describes reducing device pump rates to 1
beat per minute for periods of as long as 20 minutes to assess
full functional recovery. Has there been any thromboembolic
morbidity associated with restitution of full pump rates?
Durability of restored function is unfortunately still subop-
timal, with a substantial percentage of patients ultimately
dying or requiring transplantation after device explantation. I
would lastly like to ask you to speculate on how the durabil-
ity of myocardial recovery might be improved.
Dr Hetzer. Thank you very much, Dr Rose, for your expert
comments and questions. You were the first, to our knowl-
edge, to have observed this type of recovery, and we were
strongly stimulated by your experience and your report.
As to the questions that you have posed, the proportion of
patients that might be candidates for a recovery and that
might be candidates for explantation of a pump has probably
been looked at in a more optimistic way in the past. We have
been talking about something like 30% of patients with car-
diomyopathy who might be candidates. I am not so sure
whether we can maintain this high percentage.
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Of approximately 230 patients we have treated by assist
device implantation during this time span, 136 had IDC.
About 10% of them had a successful long-term recovery after
explantation. When we consider only those who had an api-
cal drainage pump like a Novacor or a TCI device, which I
personally believe is an essential prerequisite for recovery,
then this proportion might go up to 20% because during the
same time we had 67 patients with cardiomyopathy having
had such assist devices.
We have not had any patient with an ischemic cardiomyopa-
thy whose improvement has been sufficient to allow us to
explant the pump. However, we have seen 3 children with very
fulminant myocarditis who came to the operating room receiv-
ing closed chest massage and who, with a biventricular and
transmitral cannula assist device, made a very fast recovery,
within something like 1 or 2 weeks. Therefore, I think some-
where in between these long-term gradual recoverers, who may
have a good long-term outcome, and these very rapid recover-
ers from viral myocarditis are probably the ranges where we are
finding our patients. Unfortunately, as you already mentioned,
we have no significant or reliable data or investigations on hand
to tell us where the patients are in this broad range.
As to your second question concerning adjuvant therapy,
we have not had any experience with, for example, cell trans-
plantation, although I believe that this is a very exciting field
and may very well be applicable to these patients. We have
systematically started our patients on a regimen of β-blockers
and afterload reduction, and I strongly believe that this is very
important to have success.
As to the completeness of drainage, we have had many
patients with atrial drainage, pneumatic extracorporeal sys-
tems, and the Berlin Heart System in this study, and not one
patient with cardiomyopathy has shown significant recovery.
From this, we deduced that complete drainage of the left ven-
tricle, preferably through the apex, is an important prerequi-
site. This led to recovery also in a patient with a transmitral
cannula directly draining the left ventricle, and this patient
belongs to the group that had recurrent failure after explanta-
tion of the system. Therefore, at present, we are convinced
that complete recovery for some time is important.
The question, of course, is how long. In an earlier study,
which is going to be published soon in The Annals of
Thoracic Surgery, we speculated whether there might be an
ideal time point during the unloading period at which
explantation of the pump should be undertaken. It may be
that if we miss this ideal optimal time point, something like
cardiac atrophy may occur, and later explantation might be
less successful. However, this is all very speculative
because it refers only to very small numbers and very dis-
crete changes.
As to the fourth question, we have not seen any emboli dur-
ing the pump subtrials. Of course, we were concerned about
this, and the patients have always received extra heparin
before undergoing those pump-off trials. Durability is a very
open question, and I think nobody has an answer yet as to
how to improve durability. The most important thing is to use
reliable morphologic data. We can ascertain which patients
may have a durable recovery.
Dr O. Howard Frazier (Houston, Tex). In 1991, we dis-
charged the first patient from the hospital with an implantable
vented electric device. That patient was on the device for 504
days and then died of a stroke, but his heart at autopsy
showed marked improvement. When we removed the device,
it was working so well that we had to use him as a donor for
his liver and kidney because I did not know how long he
would have lasted.
The subsequent work that we reported invariably showed
improvement in the idiopathic myopathies of varying degrees,
but it invariably showed histologic, physiologic, and anatomic
improvement. We have since removed the device from 3
patients. The longest period since explantation is now approach-
ing 3 years, with a 5-year history of idiopathic myopathy. For
the last 2 patients from whom we removed the device, we used
a dobutamine stress test with the device off, and the patient was
heparinized to give us some guidance. I think this is one way
that you may be able to measure physiologic recovery.
I would like to remind you that every study in these idio-
pathic myopathies with prolonged unloading and with the
patient’s own heart acting as a control has shown improve-
ment in the tumor necrosis factor α level; that work was
done at Baylor. The Temple group has shown a disappear-
ance of apoptosis. We have shown a normalization of the
calcium endoplasmic reticulum function, which may be the
earliest sign of heart failure. Therefore, I think that a large
number of these patients with idiopathic myopathies will
recover.
I would like to ask you about this problem, which in
essence is a problem of the nature of the dose. How much,
and how long? Are we undertreating, or are we overtreating?
I am not sure myself, of course. I think we in the large cen-
ters are obliged to work together to try to answer those ques-
tions and perhaps save some of these patients from a needless
transplant. Have you tried something like a physiologic test
with dobutamine stress with the pump off?
Also, I am removing the pump entirely and doing a modi-
fication of a ventricular reduction procedure on these patients
at the time of explantation. I do not know whether you have
tried that or whether you are leaving the heart as is.
Dr Hetzer. Thank you very much, Dr Frazier. We have had
so many common discussions about this interesting field. As
to undertreatment or overtreatment, I would like to state again
what I said before. There may be an ideal time to explant the
pump, and this might be missed if we unload the heart for too
long; this may be disadvantageous for later recovery. This is
what we have done: Once we have seen significant improve-
ment of the cardiac function, we have turned those pumps to
a fixed rate mode to give a certain amount of extra load to
those ventricles, with the idea that they should be trained
somewhat for later removal of the device. We have no reliable
proof as to whether this is important.
We have not attempted a concomitant ventricular reduction
procedure. Once we have acquired enough experience with
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this one, which we do not yet have, ventricular reduction may
be a valid adjunct for those patients who have not reached a
complete recovery, presumably in both dimensions and ejec-
tion fraction.
Dr Hikaru Matsuda (Osaka, Japan). As was already men-
tioned, it is difficult to find out what kind of patients can have
this benefit from an LVAD, leading to the recovery. We have
been looking for morphologic changes of the left ventricle,
particularly for cell diameter and degree of apoptosis, evalu-
ating the progress or regression of the disease during the sup-
port. We have not encountered a recovery case so far, but in
10 patients we looked for serial changes of the morphologic
aspects. The ages were a little bit higher, with the mean age
about 50 years, and we believe that the disease itself was in
its very last phase. The cell diameter, fibrosis, and apoptosis
gradually increased from the time of diagnosis to the time of
the implantation of the devices, and at the time of the autop-
sy or at transplantation, it was worse. Therefore, in our
patients the evidence showed that the disease itself was pro-
gressing and deteriorating, even under the unloading situa-
tion. Dr Frazier said that there was some evidence that the
unloading prevents apoptosis, but we need to think about this
to treat more aggressively during the support so as to prevent
apoptosis or the increase of fibrosis.
Did you check the serial changes of the histologic aspects
of the left ventricle, and have you made a comparison
between the patients who recovered and those who did not
recover?
Dr Hetzer. Thank you, Dr Matsuda, for your question and
comments. In the panel of studies that are ongoing, up to now
we have not seen any reliable differences as to apoptosis and
other morphologic parameters regarding the predictability of
recovery and also the predictability of later durability of
recovery. However, we do not have serial studies. We have
not subjected those patients up to now to left ventricular biop-
sies during the assist period and afterward, which we proba-
bly should have done to obtain reliable data.
At present, we have only a core of the apex or some biop-
sy tissue at the time of implantation, but this is not conclusive
enough. I realize that if we want more precise data, we have
to be more invasive in those studies, but unfortunately, I can-
not present such information to you right now.
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